Literature DB >> 16889557

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

J E Sadler1, U Budde, J C J Eikenboom, E J Favaloro, F G H Hill, L Holmberg, J Ingerslev, C A Lee, D Lillicrap, P M Mannucci, C Mazurier, D Meyer, W L Nichols, M Nishino, I R Peake, F Rodeghiero, R Schneppenheim, Z M Ruggeri, A Srivastava, R R Montgomery, A B Federici.   

Abstract

von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF). VWD is classified into three primary categories. Type 1 includes partial quantitative deficiency, type 2 includes qualitative defects, and type 3 includes virtually complete deficiency of VWF. VWD type 2 is divided into four secondary categories. Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite a relatively normal size distribution of VWF multimers. Type 2N includes variants with markedly decreased affinity for factor VIII. These six categories of VWD correlate with important clinical features and therapeutic requirements. Some VWF gene mutations, alone or in combination, have complex effects and give rise to mixed VWD phenotypes. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889557     DOI: 10.1111/j.1538-7836.2006.02146.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  242 in total

1.  VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Authors:  Daniel B Bellissimo; Pamela A Christopherson; Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Amy D Shapiro; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Jeanne M Lusher; Margaret V Ragni; Robert R Montgomery
Journal:  Blood       Date:  2011-12-23       Impact factor: 22.113

Review 2.  Von Willebrand disease in the United States: a perspective from Wisconsin.

Authors:  Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Daniel B Bellissimo; Sandra L Haberichter; Robert R Montgomery
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

3.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

4.  Integration of molecular and clinical data of 40 unrelated von Willebrand Disease families in a Spanish locus-specific mutation database: first release including 58 mutations.

Authors:  Irene Corrales; Lorena Ramírez; Júlia Ayats; Carme Altisent; Rafael Parra; Francisco Vidal
Journal:  Haematologica       Date:  2010-08-26       Impact factor: 9.941

5.  General surgery in patients with a bleeding diathesis: how we do it.

Authors:  Kamal R Aryal; D Wiseman; Ajith K Siriwardena; Paula H B Bolton-Maggs; Charles R M Hay; James Hill
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

6.  Chitosan scaffold enhances growth factor release in wound healing in von Willebrand disease.

Authors:  Mercy Halleluyah Periayah; Ahmad Sukari Halim; Arman Zaharil Mat Saad; Nik Soriani Yaacob; Abdul Rahim Hussein; Faraizah Abdul Karim; Ahmad Hazri Abdul Rashid; Zanariah Ujang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.

Authors:  Christin R Howard; Tara L Lin; Mark T Cunningham; Brea C Lipe
Journal:  Blood Coagul Fibrinolysis       Date:  2014-09       Impact factor: 1.276

8.  An international survey to inform priorities for new guidelines on von Willebrand disease.

Authors:  Mohamad A Kalot; Mohammed Al-Khatib; Nathan T Connell; Veronica Flood; Romina Brignardello-Petersen; Paula James; Reem A Mustafa
Journal:  Haemophilia       Date:  2019-11-26       Impact factor: 4.287

9.  Optimization of the automated, CS-2000i™ method for measuring low levels of von Willebrand factor ristocetin cofactor activity (VWF:RCo).

Authors:  Tomoko Matsumoto; Keiji Nogami; Masahiro Okuda; Midori Shima
Journal:  Int J Hematol       Date:  2014-12-06       Impact factor: 2.490

Review 10.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.